TALEN-based gene correction for epidermolysis bullosa

Area of Science:

• Molecular Biology
• Genetics
• Dermatology

Background:

• Recessive dystrophic epidermolysis bullosa (RDEB) results from COL7A1 gene mutations, leading to type VII collagen deficiency.
• Current gene augmentation therapies for RDEB carry risks of insertional mutagenesis.

Purpose of the Study:

• To investigate the use of engineered transcription activator-like effector nucleases (TALEN) for precise genome editing to correct COL7A1 mutations.
• To assess the safety and efficacy of TALEN-mediated gene correction in RDEB patient cells.

Main Methods:

• TALEN technology was employed to induce site-specific double-stranded DNA breaks (DSBs) for homology-directed repair (HDR) using an exogenous donor template.
• Primary fibroblasts with COL7A1 mutations underwent gene correction, were reprogrammed into induced pluripotent stem cells (iPSCs), and evaluated in vivo using a teratoma-based skin model.
• Deep sequencing was used for genome-wide screening to identify on-target and off-target (OT) activities.

Main Results:

• TALEN successfully induced HDR, correcting the COL7A1 gene mutation in patient-derived fibroblasts.
• Corrected iPSCs demonstrated normal type VII collagen protein expression and deposition in an in vivo skin model.
• Genome-wide screening identified three OT loci located at least 10 kb from coding sequences, indicating a favorable safety profile.

Conclusions:

• TALEN-mediated in situ correction of endogenous COL7A1 mutations is a viable proof-of-concept strategy for RDEB.
• The study provides a comprehensive TALEN target mapping, facilitating future translational applications for RDEB gene therapy.